The information provided herein is generated by experimental artificial intelligence and is for informational purposes only.
merck acquires chinese cancer antibody in deal worth up to 3.3 billion
Merck & Co. has entered into a deal with LaNova Medicines Ltd. to license an experimental cancer antibody, LM-299, for $588 million upfront, with potential milestone payments reaching up to $2.7 billion. This agreement enhances Merck's focus on dual-targeted antibodies, providing exclusive global rights to the bispecific antibody that targets cancer through multiple mechanisms.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.